Sarcoma cancer patients not receiving same protection from Covid-19 as healthy population due to Pfizer vaccine spacing: Sarcoma UK, the national bone and soft tissue cancer charity, is concerned to hear that a new study suggests cancer patients are not receiving the same protection as others against Covid-19 following one does of the Pfizer vaccine.
Sarcoma is a type of cancer that develops in the bone and soft tissue. It is difficult diagnose and one of the hardest to treat.
Sarcoma UK is calling on the Government and the Joint Committee on Vaccination and Immunisation (JCVI) to review the results of the study and consider adapting its strategy so that people with cancers can access the second dose of the vaccine more quickly.
Richard Davidson, Chief Executive of Sarcoma UK, said:
‘It’s really worrying to hear that some cancer patients are not receiving the same levels of protection from the virus as healthy people. This news has caused great anxiety for sarcoma patients, whose cancer and its treatment are already seriously compromising their immune systems. A review of the current spacing strategy for the vaccine is needed to ensure the best level of protection for these clinically vulnerable patients.’
Helen Stradling, Support Line Lead said:
‘This is worrying news, but we urge anyone with sarcoma to continue to follow the advice of their treating teams. Anyone who is offered the vaccine should take it and continue to follow government guidelines on shielding and social distancing.’
About sarcoma
- Sarcomas are uncommon cancers that can affect any part of the body, on the inside or outside, including the muscle, bone, tendons, blood vessels and fatty tissues.
- 15 people are diagnosed with sarcoma every day in the UK. That’s about 5,300 people a year.
- There are around 100 different sub-types of sarcoma.
Sarcoma UK is a national charity that funds vital research, offers support for anyone affected by sarcoma and campaigns for better treatments. It is now one of the biggest funders of sarcoma research in the UK, having invested more than £3.5 million to 56 research projects to date. Sarcoma UK’s Support Line has helped more than 2,500 individuals through calls, emails and texts since 2016. sarcoma.org.uk
 logo final copy.png)
- HPV Vaccine’s Effectiveness Remains High Amidst Uptake Concerns - 26th April 2024
- Global immunization has saved at least 154 million - 26th April 2024
- Top Tips To Detox Your Mind and Body - 26th April 2024
